Because highly variable results have been reported even from the same histological tumor subtype in different studies using different experimental conditions and scoring criteria, it appears likely that many of the controversial data in the literature are due likely due to the use of different antibodies, immunostaining protocols, and criteria to categorize E-Cadherin in these studies. Here, CDH1 is linked to neoplasm.